PIOLAX (5988) Q2 2025 earnings summary

Executive summary

• Sales increased in 1H FY2024, driven by strong performance in North America and the medical device business, but profits declined due to reduced production by major Japanese OEMs and the absence of weak yen effects.

• Net sales rose 3.2% year-over-year to ¥31,946 million for the six months ended September 30, 2024.

• Operating income declined 32.4% year-over-year to ¥1,271 million, and net income attributable to owners dropped 38.1% year-over-year to ¥1,225 million.

• Full-year forecasts have been revised downward, and the medium-term management plan is under review due to significant changes in the business environment.

• Strategic focus is on CASE (Connected, Autonomous, Shared, Electric) automotive products, regional diversification, and expanding the medical device business.

Financial highlights

• FY2024 sales forecast revised to ¥63,500 million, down 1.6% year-over-year; operating profit forecast at ¥2,400 million, down 49.5% year-over-year.

• Net income attributable to owners is forecast at ¥2,200 million, a 45.2% decline year-over-year.

• Net income per share for the year is expected to be ¥64.59.

• Operating profit ratio expected to decline to 3.8% in FY2024 from 7.4% in FY2023.

• ROE for FY2024 is 2.9%, with a target of 8% or more by FY2026.

Outlook and guidance

• Full-year forecasts revised downward due to ongoing weak production by Japanese OEMs in Japan and China.

• Medium- to long-term growth targeted through investment in high-potential regions (North America, India) and product development.

• ROE target set at 8% or more by FY2026.